Discover how mirdametinib, a next-generation MEK1/2 inhibitor originally developed for MAPK-driven tumors, is emerging as a promising tool to modulate ERK signaling, improve synaptic plasticity, and potentially treat treatment-resistant depression beyond traditional monoamine-based antidepressants.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs